Sandra Levy
ARTICLES BY THIS AUTHOR
- 9/20/2022
Hikma intros 2 injectables
The company is offering bortezomib for injection 3.5 mg and ulvestrant injection 250 mg/5 ml. - 9/19/2022
AAM reacts to Avalere study on generic drug costs
The Avalere analysis shows that generic drugs continue to be misplaced on higher formulary tiers, unfairly driving up costs for patients. - 9/19/2022
Amazon to bring low carbon electrofuels to its trucking fleet
An agreement with Infinium will help Amazon reduce carbon emissions for roughly 5 million miles of travel per year, the company said. - 9/19/2022
Walgreens Boots Alliance takes full acquisition of Shields Health Solutions
WBA is acquiring the remaining 30% stake of Shields (approximately 35% on a fully diluted basis) for approximately $1.37 billion. - 9/18/2022
Bausch Health responds to Norwich Pharmaceuticals’ tentative FDA nod for rifaximin
Xifaxan 200 mg is indicated for travelers' diarrhea and currently contributes less than 1% of Salix’s revenues. - 9/18/2022
Albertsons, Kelloggs to feed children in need
During the month of September, Albertsons Co.'s shoppers can donate during checkout to support Nourishing Neighbors. - 9/18/2022
Instacart rolls out Connected Stores technology
Instacart's Connected Stores consists of six new Instacart Platform offerings: Caper Cart, Scan & Pay, Lists, Carrot Tags, FoodStorm Department Orders and Out of Stock Insights. - 9/18/2022
McKesson to acquire Rx Savings Solutions
The acquisition aligns with McKesson’s strategic growth focus by connecting biopharma and payer services to patients, the company said. - 9/15/2022
Dr. Reddy’s debuts generic Revlimid
Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for lenalidomide capsules in 2.5-mg and 20-mg strengths. - 9/15/2022
FDA gives AstraZeneca approval for Imfinzi
Imfinzi is used to treat adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy (gemcitabine plus cisplatin).
